西北大学-艾比玛特 招聘宣讲会

活动时间:7月6日 周四下午5:30
活动地点:icahn 101
活动主题:西北大学-艾比玛特应用抗体技术研究所 美国招聘行
报名方式:发参会场次、姓名、联系方式至TalentRecruiting@nwabi.cn

地处西安的西北大学和上海的抗体技术公司艾比玛特联合成立了“西北大学-艾比玛特应用抗体技术研究所”,为中国第一个大学-公司联合成立的高端生物技术研究和转化研究所,为广大优秀的年轻科学家提供一个集一流科学研究和诊断/制药产品化的平台,实现“西凤筑巢东方之珠”项目的人才引进。

研究院将聚焦应用抗体技术研究,再生生物学/医学,精准医学,肿瘤免疫治疗,细胞治疗,检测技术等方向,设立一批技术攻关研究项目,发展引领产业变革的颠覆性技术,开辟产业发展新方向,培育新经济增长点。

研究院招聘行将在美国东部七所大学及清华大学美国校友会(纽约市)对西北大学-艾比玛特应用抗体技术研究院的人才招募计划做详细介绍,同时就研究院在精准医疗,肿瘤免疫/细胞治疗,抗体药等领域的研究方向做进一步的互动和说明。欢迎有兴趣的同学报名参加在普林斯顿的招聘宣讲会。

如果您有兴趣参加,可通过邮件方式报名。活动报名联系邮件:TalentRecruiting@nwabi.cn,请提供您期望参加的场次学校(i.e. 7/6 普林斯顿),您的姓名及联系方式。您还可点击这里,了解更多。

 

 

哈尔滨工业大学-招聘宣讲会

下周四,我们将迎来哈尔滨工业大学的招聘宣讲会。6月22日中午11:30-13:30,哈尔滨工业大学将于Lewis Library 120举办专场招聘宣讲会。欢迎感兴趣的同学前来参加。同时您若想了解更多关于哈尔滨工业大学招聘宣讲会的信息,请点击下方链接。ACSSPU将在宣讲会现场恭候您的到来。

活动时间:6月22日 中午11:30-13:30
活动地点:Lewis Library 120
活动主题:哈尔滨工业大学招聘宣讲会
活动详情:点击这里

ICBCCS 2017 Summer Internship Program

ICBC Credit Suisse Asset Management Co., Ltd

ICBC Credit Suisse Asset Management Co., Ltd. (“ICBCCS”) is a fund management company established jointly by Industrial and Commercial Bank of China and Credit Suisse A. G. in June 2005. By far, ICBCCS has established branches in Beijing, Shanghai, Shenzhen, as well as wholly-funded subsidiaries, ICBCCS Asset Management (International) Co., Ltd. in Hong Kong and ICBCCS Investment Management Co., Ltd. in Shanghai.

Since its inception, the Company has upheld the mission of “Providing Excellent Wealth Management Services for Clients with Prudent Investment”. With its strong shareholders’ support, prudent management philosophy, scientific investment & research system, robust risk control system and experienced senior management team, the Company has been committed to providing world-class investment management services to investors in a professional and standardized manner that is up to the international standards, based on the principle of “prudent investment, value-oriented investment and long-term investment”.

Adhering to the “talents-oriented” notion, the Company has attracted talents from home and abroad and has built a credible, diligent, enterprising, collaborative and  professional team. By now, the Company has over 550 staff members whose average age is 32. 72% of the staff have master’s degree or above. The Company’s investment & research team is composed of seasoned fund managers and researchers. There are more than 170 experienced researchers. The investment managers have an average of approximate 10 years’ experiences in the industry..

After more than a decade of development, ICBCCS has become an all-around asset management company with its business landscape extending to mutual funds, separately managed accounts (SMAs), corporate annuities, entrusted investment of social security funds in China and abroad, investment management of basic pension funds, entrusted investment of insurance funds, old-age pension products, QDII, QFII and RQFII among others. The Company has provided complete wealth management services to more than 16 million domestic and foreign individual and institutional investors by offering mutual funds and private equity products and engaging in listed and non-listed related businesses as well as domestic and cross-border businesses.

Since its establishment, the Company has been well recognized and trusted by its fund investors, the National Council for Social Security Fund, corporate annuity clients, as well as the SMA investors with its continuous outstanding investment performance and comprehensive and thoughtful client services. As of December 31, 2016, ICBCCS and its subsidiaries managed nearly 100 mutual funds and many annuities and SMAs portfolios, with its assets under management (AUM) exceeding RMB1.1 trillion. The mutual funds manage over RMB 460 billion. The Company has developed into a fund management company with comprehensive business qualifications, complete product lines, excellent investment performance, leading AUM and balanced business development.

Company URL:http://www.icbccs.com.cn/gyrx/about/cpyc/pages/1.html

 

Job Needed

Location: Beijing 

Investment research:

  1. Assistant Researcher
  2. Assistant Quantitative Researcher
  3. Index Fund Sales Assistant
  4. Capital Distribution Assistant Researche
  5. Fund Selection Assistant Research
  6. Strategic Program Assistant
  7. Central Trade Office, Trader
  8. Bond Trader
  9. Stock Trader

Marketing:

  1. Sales support
  2. Sales assistant

Central and Background:

  1. Product development assistant
  2. Assistant Quantitative Analyst
  3. Legal & Compliance Assistant
  4. HR assistant
  5.   Finance assistant
  6. System develop assistant
  7. Fund accountant

Requirements:

  1. Master students will graduate before August 2018, and major in Economics, Finance, Accounting, Computer and other related majors.
  2. Preferred internship experience in fund and capital management
  3. Preferred students who have fund qualification certificate
  4. Good communication ability
  5. High responsibility, good team work
  6. Strong learning ability

Internship Period:From June to August, 2017

Recruiting Process:

Apply——CV filter——Writing test——Interview——Intern offer——Summer internship——Internship presentation

Public Application Pathway: http://campus.chinahr.com/2017/gyrx/index.html

Or log in official website:http://www.icbccs.com.cn/gyrx/about/cpyc/pages/1.html

Apply Closing Time:May 31st, 2017

毕业沙龙:普林斯顿大学华人职业分享会

时间:2017年5月18日星期四5:30PM (提供晚饭)

地点:Friend Center 004

主办方:普林斯顿中国学生学者联合会

报名方式:点击下方链接填写报名表格

又是一年一度的毕业季,大家是否开始思考职业规划了呢?别着急,普林斯顿大学中国学联为大家请到了五位博士毕业并将于各行各业就职的学长学姐,与大家分享他们一路走来的感悟和心得。如果你对博士毕业后的未来有很多迷茫和疑惑,希望能有前辈高人为你答疑解惑,指点迷津,请千万不要错过这次当面请教并与学长学姐建立长期联系的机会。

这几位学长学姐分别是:

汪昭然

本科毕业于清华大学电子工程系,普林斯顿大学运筹与金融工程系(ORFE)博士在读,科研方向是机器学习和统计优化,毕业后将就职于西北大学IEMS,同时也获得了芝加哥大学Booth商学院、康奈尔大学ECE、卡内基梅隆大学Tepper商学院等教职机会。

陈昱

本科毕业于清华大学,普林斯顿大学电子工程系博士在读(ELE),毕业后将就职于Morgan Stanley。博士期间曾于IBM T. J. Watson担任summer research intern。

沈煜

本科毕业于中国科学技术大学少年班理科试验班物理方向,普林斯顿大学物理系博士在读,科研方向是凝聚态理论,毕业后将就职于Wells Fargo Securities,对咨询公司,对冲基金,投行等多个行业有求职经历。

张天威

本科毕业于北京大学,普林斯顿大学电子工程系博士在读,科研方向是云计算系统安全,毕业后将就职于Amazon Web Services。博士期间曾于Siemens Research以及Amazon Web Services担任intern。

孙伟奇

本科毕业于北京大学元培学院物理方向,普林斯顿大学机械工程系(MAE)博士在读,科研方向为燃烧领域的CFD数值模拟。毕业后将就职于Bloomberg,博士期间曾于CD-Adapco担任Software Engineer。

看了以上大牛的简介,有没有充满期待呢?

另外,本学期的Chinese Lunch已经结束一周啦,大家是不是已经开始无尽的思念(星星眼)?没关系,我们ACSSPU再来给大家送温暖!沙龙当天我们会再次提供人见人爱花见花开的Chinese Lunch,而且免费哦!名额有限,请速速点击下方链接报名!我们期待与你一起品Chinese Lunch,聊人森理想!

报名链接:https://docs.google.com/forms/d/e/1FAIpQLSdjZW4TSFq7G08DO9-UjX88O8-QlCQTfk4O-f3UmZr5EdZ1ow/viewform

山西大学哲学社会学学院诚招海外英才

山西大学哲学社会学学院诚招海外英才

山西大学哲学社会学学院诚招海外英才回国任教,待遇优厚。热诚欢迎有意回国效力的博士生朋友们与我们联系。

 

专业要求:哲学、社会学、社会工作及相近学科专业;

履历要求:海外博士毕业生或毕业后有一定学术工作经历者均可报名;

工作待遇:实行一人一议,按需支持,有意向者可与学校单独商定;

聘任方式:经报名和面试通过后,双方商定聘任方式。

联系邮箱:gojbo@sxu.edu.cn;

 

学院简介:山西大学哲学社会学学院成立于1980年,拥有一流的办学条件,教学科研用房6000余平米,包括独立的图书馆、实验室、报告厅、教室及教师工作室,配备有精干高效的管理服务团队。有哲学博士一级学科授予权和社会学、人口学硕士一级学科授予权,开设哲学、社会学和社会工作三个本科专业。哲学学科在国内排10名上下,设有科学技术哲学、马克思主义哲学、中国哲学、西方哲学四个主要研究方向,设有哲学博士后科研流动站。其中科学技术哲学为国家重点学科,山西省唯一的教育部人文社会科学重点研究基地,主办有国内本专业的三大权威期刊之一《科学技术哲学研究》,学科在国内排名第一,属于5星专业。马克思主义哲学独具特色,尤其是英国新马克思主义哲学研究在国内产生了重要影响,属于4星专业。

山西大学哲学社会学院以优厚待遇及一流的工作条件吸引海内外优秀学者、博士生,全职或半职来学院工作,为其解决家庭及生活等后顾之忧,实行一人一议一策,根据人才的不同情况,为他们提供个性化工作生活和发展平台。

学校历史:山西大学,位于山西省省会太原市,由英国人李提摩太和时任山西巡抚岑春煊共同创办,是中国创办最早的三所国立大学之一。学校前身可追溯到明清晋阳书院和令德堂书院,民国初改名为山西大学校,1918年确定为国立山西大学,1931年改名为山西大学。

山西大学是中西部十四所国家重点建设大学之一,山西省人民政府与教育部共同重点建设的综合研究型大学,“中西部高校综合实力提升工程”(一省一校)大学,“中西部高校基础能力建设工程”大学,中西部“一省一校”国家重点建设大学(Z14)联盟成员,国家理科基础科学研究和教学人才培养基地,国家首批“卓越法律人才教育培养计划”高校,“全国九所地方综合性大学协作会”成员,“中国政府奖学金来华留学生接收院校”,山西省综合改革试点高校,拥有研究生院和“推荐免试研究生”、“教授评审”资格。

撰稿人:丁剑

McKinsey & Company’s Insight Asia Pacific Program 2017

Deciding what to do after you finish your advanced degree? Consider management consulting and McKinsey. We bring together an outstanding group of colleagues, from a wide variety of backgrounds – from medicine to law, engineering, economics and digital – to help leading organizations tackle their most complex challenges. We have long been a leader in strategic management; the amount of work we are doing in areas such as data science, software engineering, machine learning, corporate restructuring, and change management is growing rapidly. As our firm evolves, we are looking for more and more people like you – experts in their fields – to join our community.

At McKinsey, you’ll find a home in one of our 110+ offices around the world. You may work in any one of 22 sectors – from high tech to healthcare – and/or 12 business functions – from marketing & sales to analytics or sustainability – serving clients in all sectors. You may continue to dive deep into your existing area of expertise or explore new subjects. You’ll put your hypothesis-based problem-solving skills to use while receiving the mentorship and support you need to succeed. No matter your educational background or interests, you will shape a career that fits your calling.

We welcome you to learn more about exciting programs and roles available to you at McKinsey, including a great lineup of summer-long weekend experiences. In particular, we wish to highlight our Insight Asia Pacific ProgramInsight 2017 This exciting 3-day summer program from June 18-21 gives non-MBA advanced degree students an insider’s look into management consulting, covering a range of topics important to those who are exploring alternative career possibilities.  The program’s agenda includes an overview of management consulting, an introduction to the type of work we do, a management consulting case study and participate in social activities in the city of Chicago. It also gives you a great opportunity to network with colleagues from our Asia Pacific offices and learn about this exciting region.

Insight Asia Pacific is for students dedicated to starting a career with McKinsey in Asia Pacific (Australia, Greater China, India, Indonesia, Japan, Korea, Malaysia, Philippines, Singapore, Thailand, Vietnam, or any of our Digital McKinsey and Operations offices in Asia Pacific).  Applicants should be fluent in English and one of the following languages (based on office interest): Bahasa, Japanese, Hindi, Korean, Malay, Mandarin (Cantonese preferable for Hong Kong), Tagalog/Filipino, Thai, or Vietnamese (or English alone for those interested in Australia).

Web Events: This March, we are hosting several web-based presentations to help you learn more about McKinsey and our global opportunities. Please visit the Online Events section of our website for details on these presentations and to RSVP. Please note that our Asia Pacific office web-based presentation will take place on March 23 at 7:00pm EST.

Dropbox: Check out additional content in our Advanced Professional Degree Recruiting Dropbox, including information on the full time hiring process and our 3-day Insight programs this summer. You can download the Dropbox app for your phone or access on your computer: APD Opportunities Dropbox.

We aspire to be the best professional services firm in the world for all of our colleagues, regardless of race, gender identity, sexual orientation, or background. To learn more about McKinsey Women, please view our women’s brochure. To learn more about our other diversity networks, including the McKinsey Black Network, the Hispanic and Latino Network, and GLAM (LGBTQ colleagues at McKinsey), please visit the Diversity & Inclusion section of our website. Additionally, we invite you to join us for a few of our upcoming diversity related web-based presentations in March.

McKinsey & Company select practice information:

Digital McKinsey (over 12 locations in the Asia Pacific region): Digital McKinsey offers candidates an exceptional opportunity to work at the intersection of Digital, technology and business. We help our clients embark on end-to-end digital transformations, creating value by reinventing the core of their businesses.  If you have a passion in digital, and joining a smaller community appeals to you, you should consider Digital McKinsey.

Operations (over 18 locations in the Asia Pacific region): The Operations Practice helps our clients transform every aspect of their operations, from manufacturing to customer support. Our impact is seen in dramatic improvements in efficiency, productivity, quality and flexibility.  If you have a high interest in Operations as well as you having some Operations background, you should consider the Operations Practice.

We look forward to getting to know you more and are happy to answer any questions.

Kind regards, Lizzie Kothari (McKinsey Asia Pacific office Recruiter)

______________________________________________________________________________
Lizzie Kothari / McKinsey & Company, 1800 Larimer St. | Suite. 2210 | Denver, CO  80202 / T. +1 312 363 7639

南方科技大学教授招聘宣讲

时间:2月11日(周六),下午14:30

地点:Frist campus center 302

宣讲人: 程鑫 教授 (南方科技大学材料科学与工程系系主任)

现场提供晚餐、饼干及软饮料

14:30Feb. 11 (Saturday)

Frist campus center,room 302

Speakers:

Prof. Xin CHENG (Chair of the Department of Materials Science and Engineering)

All welcome! Food,snacks, and soft drinks will be served at the event!

南方科技大学简介

南方科技大学是由中国广东省领导和管理、深圳市举全市之力创办的一所全日制公办高等学校。作为国家高等教育体制改革的试验学校,南科大将为中国新型现代大学的制度建设发挥示范效应。

南科大目前教师总数268位,其中院士14位,长江学者12位,千人计划人才34位,青年千人计划人才60余位。2016年以我校为依托单位成功申请到青年千人14名,居全国第九名,成绩瞩目。2016年,南科大取得多项突破性的成果:获得各级各类科技项目总计197项, 总获批经费3.72亿元, 人均项目费约200万元;“自然指数2016新星榜”增刊显示,在全球100家高质量科研论文增长最显著的国家和机构中。南科大排名第62位,增速高达2442.5%,排全球第3位。

欢迎海内外青年学者踊跃报名和咨询!

 

南方科技大学材料科学与工程系教授招聘

南方科技大学材料科学与工程系诚邀海内外优秀学者加盟!诚招理论与计算材料科学、航空航天材料、能源材料、信息(电子,光学和磁性)材料、生物材料、先进材料制造和表征。

应聘者应具有相关学科的博士学位和优秀的学术发表记录,并具备出色的沟通和教学能力。终身职位的候选人必须为国家和国际认可的知名学者。南方科技大学为受聘教授提供具有国际竞争力的薪酬和福利,优越的科研环境,以及充裕的科研启动资金。千人计划、孔雀计划等其他人才项目获选人将获得中央及深圳市给予的额外资金支持。

应聘者请登录南方科技大学在线招聘网站http://talent.sustc.edu.cn直接提交申请,并将下述申请材料的电子版打包发送至qinsh@sustc.edu.cn 或 liurx@mail.sustc.edu.cn(纸质版简历可自愿在宣讲现场提交):

1 个人简历(包括完整的学术论文列表)

2 研究兴趣与计划陈述

3 教学理念陈述

4 五篇代表性论文全文

5 三封推荐信

材料科学与工程系未来发展规划将兼顾前沿科学性、国家学科战略发展规划、及广东省和深圳市的产业布局,重点发展能源材料与器件、有机电子、生物和医学材料、信息材料、软物质材料、航空航天材料、高端制造技术(包括粉末冶金和增材制造)、微纳结构加工与应用等八个方向,力争十五年内建成国际知名的材料学科研究基地。目前共有集成宏电子实验室、先进材料-微纳结构调控与应用实验室、清洁能源材料制备实验室、绿色可再生能源实验室、印刷有机晶体管和电路实验室等17个实验室,其中深圳市重点实验室4个,孔雀团队2个。

第二届“百名海外名校博士创业中国行”活动通知

为落实党的十八大、十八届三中全会关于实施创新驱动发展战略,响应国家“大众创业,万众创新”的号召,深入贯彻习近平总书记在欧美同学会成立100周年庆祝大会上的讲话及 2016年5月中共中央办公厅印发的《关于加强欧美同学会(留学人员联谊会)建设的意见》精神,发挥我会特点和优势,为实现中华民族伟大复兴“中国梦”服务。欧美同学会定于12月18日至24日在北京、广州、宁波举办第二届“百名海外名校博士创业中国行”活动。该活动在广州部分已经列为2016中国海外人才交流大会暨第十八届中国留学人员广州科技交流会活动主要内容之一。

详细活动方案及报名表等信息见附件。本次活动的报名截止日期为2016年11月30日,请及时将报名表发送到工作邮箱。会议组织方将承担您参加本次活动的交通食宿费用。

请将报名表发送至:wrsaphd@163.com

联 系 人:朱宁新

联系电话:01065122800/18810111769

联系微信:wrsa-cosa

校友职业发展交流讲座系列第四期​—生物医药行业机会分析与职业发展规划

近期到来的年轻校友们希望能多了解各行业状况和市场形势,也渴望在如何规划职业发展,培养职场能力,找到理想的工作等方面得到指导和建议。应校友们的需求,多所大学校友会联合学生组织共同举办系列职业发展交流讲座来促进校友间的职业经验与智慧的分享交流,帮助年轻校友职业发展,加深校友间的紧密联系,让大家共同进步。

生物医药行业近些年发展迅速,中美医药行业的广泛合作也促进了中国生物医药也的快速进步,所以在美国和中国生物医药各领域机会很多,但竞争也很激烈。如何在生物医药业取得一席之地,并成功驾驭职业发展是众多校友们关注的话题。我们将生物医药行业机会分析和职业发展规划作为主题来做第四期讲座。为此我们邀请到了几位生物医药领域经验丰富的专家和最近刚成功找到工作的校友来给大家做分享和互动交流。

他们的专业领域覆盖生物医药研发,临床实验,项目管理,生物统计,专利申报,以及对外合作和项目引进等。特邀分享嘉宾包括:

Frank Gan         Director, Clinical Research, Johnson & Johnson

Jimmy Hao       Attorney at Law and registered US Patent Attorney, FoxRothschild LLC

Guanghui Hu President and CEO, Admera Health

Mike Hu Senior Director, Clinical Development, Jazz Pharmaceuticals

Jerry Jing Li       Associate Principal Scientist, Global Clinical Development, Merck

Jian Liu Principal Scientist, External Discovery Chemistry, Merck

John Sun           Global Project Manager, Novartis (Moderator)

Bing Yuan         Executive Director, Oncology Business Development, Merck

时间:11/19日,星期六,下午2点到6点

地点:701 West 168th Street, Hammer Health Sciences Building, Room 401, New York, NY 10032

费用:$10 (提供饮料和snacks)

注册:因场地位置有限,请务必用此链接注册

https://www.eventbrite.com/e/29302735270

主办单位:武汉大学大纽约地区校友会,北京大学大纽约地区校友会,大纽约地区清华校友会,天津大学(北洋大学)北美校友会, 北美浙江大学校友会大纽约分会,华中科技大学大纽约校友会,中国科技大学大纽约校友会, 南京大学大纽约校友会,复旦大学美国校友会纽约分会,纽约南开校友会,中央财经大学美国校友会,交通大学美洲校友会大纽约分会,美中医药开发协会(SAPA)

协办单位:哥伦比亚大学医学院中国学生学者联谊会

嘉宾简介:

Frank Gan, Pharm. D.

Clinical Research Director

Oncology Department, Johnson & Johnson

Frank is a clinical research director working at Janssen Oncology Department. He was a bench scientist with experiences working in both academic and biopharmaceutical industry. He switched his career path from preclinical to clinical research more than 12 years ago while working at Merck. He has extensive hands-on working experiences in Phase 1, 2 and 3 clinical trials with both small molecules and biologic drug candidates, and has successfully managed several global clinical trials in metabolic disease and oncology areas while working at Merck, BMS, and Eli Lilly.

 

Frank received his Bachelor and Master degrees in pharmaceutical sciences from Shanghai Medical University and earned his Pharm.D. degree from Shenandoah University.

Jianming Jimmy Hao (郝建明), PhD, JD

Attorney at Law and registered US Patent Attorney, Intellectual Property (IP) Department, Fox Rothschild LLP

Mr. Hao is an attorney at law and registered U.S. patent attorney with the Intellectual Property (IP) department of Fox Rothschild LLP, a prominent national general practice law firm. With more than a decade of legal experience, he serves as counsel to many clients including Fortune 100 companies, startups, entrepreneurs, investors, and academic institutions in biotechnology and pharmaceutical industries on a broad range of business and legal issues, including patent, trademark, licensing, litigation, VC financing, and M&A. He has prosecuted thousands of patent applications nationally and internationally, including portfolios that resulted in over $47 million venture financing and $51.5 million acquisition.

Mr. Hao has provided legal representation to several notable business transactions, including Alexion Pharmaceuticals Inc.’s acquisition of Synageva BioPharma Corp (valued at $8.4 billion), Humanwell Healthcare Group and PuraCap Pharmaceutical’s acquisition of Epic Pharma (valued at $550 million), BMS’s acquisition of Amira Pharmaceuticals (valued at $475 million), licensing and collaboration deals involving companies including Merck, Alnylam, and others.

Mr. Hao received a JD from Boston College Law School, a PhD from Columbia University, an MBA from Cornell University, and a BS from Nankai University. Prior to his legal career, he conducted research on neural and heart development at Columbia University as a graduate student. During his time at Columbia University, his PhD thesis was awarded With Distinction. He later held a postdoctoral fellowship at Harvard Medical School where he conducted research on oncology, immunology, and stem cells.

Guanghui Hu, Ph.D.President & CEO, Admera Health

Dr. Guanghui Hu is the President and co-founder of Admera Health. Previously, Dr. Hu served as Vice President and Global Business Leader of Translational Genomics at GENEWIZ, Inc. Prior to joining GENEWIZ, Inc., Dr. Hu acquired over 12 years of drug development and management experience in the pharmaceutical industry at companies including Merck and GlaxoSmithKline. Dr. Hu completed postdoctoral research at the University of California Los Angeles after earning his Ph.D. from Baylor College of Medicine, holds a Master of Science degree from the Chinese Academy of Sciences, and a Bachelor of Science degree from Tsinghua University. Dr. Hu is also a member of the American Society of Clinical Oncology.

Mike Hu, Ph. D.

Senior Director

Clinical Development, Jazz Pharmaceuticals

Dr. Mike Hu, Ph.D., has over 17 years of experience in clinical and pre-clinical R&D of drugs in multiple therapeutic areas: oncology, hematology, endocrinology, metabolic, viral, and rare diseases. Dr. Hu is Senior Director at Jazz Pharmaceuticals, Clinical Development, Hematology & Oncology at Ewing, NJ, since September 2016. Prior to joining Jazz, he was Director at Novartis Oncology, Clinical Pharmacology, Global Clinical Development & Medical Affairs at East Hanover, NJ. In the past 10 years from 2006 to 2016 at Novartis Oncology, Dr. Hu contributed to 6 drugs’ full clinical development, 6 global submissions/approvals, and 11 on-market drugs’ life cycle management with multiple billion-dollar franchises. Dr. Hu was involved in hundreds of clinical trials from Phase I, II, III to IV stages. He took management and leadership roles at Clinical Pharmacology Department, Global Project Teams, Oncology Protocol Review Committee, and other forums. He was receipt of Novartis President Award, Vision Award, Global Product Strategy Business Excellence Award, and Passion/Quality/Speed Award for many times. Before joining Novartis, Dr. Hu was Principal Scientist at GSK (GlaxoSmithKline), Metabolic & Viral, Drug Metabolism & Pharmacokinetics, Center of Excellence for Drug Discovery at Research Triangle Park, NC, from 2004 to 2006. He contributed to 2 drug candidates from early discovery, candidate selection to IND stage. Before joining pharmaceutical industry, Dr. Hu was postdoctor and Research Fellow at Yale University School of Medicine, Roswell Park Cancer Institute, and State University of New York at Buffalo, with focus on molecular pharmacology, biochemistry, pharmacokinetics, pharmacodynamics, drug metabolism and transporter in oncology drugs. He received Bachelor in Pharmacy and Ph.D. in Pharmaceutical Sciences at Shenyang Pharmaceutical University, China, with international exchange program at University of Tokyo, Japan. Dr. Hu has authored 51 peer-reviewed papers, 30 congress abstracts, 5 patents, 2 proceedings, and 1 book chapter. Before joining industry, he served as editor board for 4 journals, peer reviewer for >30 journals, and consultant for 2 medical groups.

Jerry Li, Ph.D.

Associate Principal Scientist

Global Clinical Development

Merck & Co, Inc.

Dr. Jerry Li is currently focused on late phase (Phase 2 and 3) clinical trials at Biostatistics and Research Decision Sciences (BARDS) within Global Clinical Development (GCD), Merck. Dr. Li obtained his Ph.D. degree in Statistics from University of Maryland, College Park.  Dr. Li joined Merck in 2013 following two years at Center for Drug Evaluation and Research (CDER), FDA.  At Merck Dr. Li has provided critical support for clinical trial design, protocol development, statistical analysis, trial monitoring as well as authoring clinical study report (CSR) and common technical documents (CTD) for new drug application (NDA) filing to regulatory agencies worldwide including U.S. FDA and European Medicines Agency (EMA). His expertise covers multiple therapeutic areas including oncology, infectious diseases, immunology and neurosciences. Several NDAs have been approved under Dr. Li’s lead and support. Some of them were delivered under extremely tight timelines. Dr. Li has published numerous peer-reviewed articles in both discovery and clinical areas. Dr. Li holds a Ph.D. degree in molecular cell biology. Dr. Li is currently a member of 2016-2017 Executive Council of Sino-American Pharmaceutical Professionals Association (SAPA).

Jian Liu (刘建), Ph. D.

Principal Scientist

External Discovery Chemistry, Merck

Dr. Jian Liu obtained a Ph.D degree in organic chemistry from UCLA in 1998 and did postdoctoral researches afterwards at UC Irvine and University of Pennsylvania. He joined the medicinal chemistry department in Merck Research Laboratory at Rahway site in Feb, 2001. Dr. Liu has worked on and managed projects on target validation, lead identification, and lead optimization and have generated multiple clinical candidates which went into first in man, phase I, and phase II clinical trials. Dr. Liu is an expert in drug discovery for many therapeutic areas such as osteoporosis, obesity, diabetes, cardiovascular disease, rheumatoid arthritis, oncology and infection disease.  Dr. Liu has also been in charge of outsourcing effort with several external companies. Based on his research work, Dr. Liu has published over 70 peer reviewed papers, patents and patent applications. Dr. Liu had worked as a lecturer at Tsinghua University for four years before he moved to the US. He is currently the 2016-2017 president-elect of Sino-American Pharmaceutical Professionals Assoication (SAPA), He has been an executive member of SAPA during the past three years, as the director of SAPA Career Development and Continuing Education committee in 2014-15 and the director of Bussiness Development and Service Department in 2015-16. He was the chair for 2015 SAPA Career Development Workshop and 2016 SAPA Scientific Symposium.

John Sun (孙壮), PhD, MBA, PMP

Global Project Manager, Global Development Operations, Novartis

John is a passionate career planning and development practitioner and advocate. He is the Global Project Manager of Global Development Operations at Novartis. Other than his responsibilities at work, John is an active volunteer in various professional organizations, including SAPA Executive Council Member, Chair of DIA Project Management Community, and Chair of Chinese Culture Community at Novartis. He had also served as Vice-President of Novartis Toastmasters Club and the Area Director of Toastmasters International.  John had presented in various domestic and international symposia on project management and drug development.

Previously John served as Global Program Team Director in the Established Medicines Development Franchise at Novartis. Before joining Novartis, John holds positions of project management and pharmaceutical research with increased responsibilities from Whitehall-Robins, Kos Pharmaceuticals, Schering-Plough, and Sanofi-Aventis. John obtained his PhD in pharmaceutics from the Virginia Commonwealth University, MBA from the Rutgers University, and BMed from the Beijing University of Chinese Medicine. John is a certified Project Management Professional (PMP).

Bing Yuan, PhD, MBA

Executive Director and Global Lead

Oncology Business Development, Merck

 

Dr. Bing Yuan is an oncology business executive experienced in business development, new product strategy, global product launch and brand life cycle management. At various stages, he made key contributions to 7 oncology drugs: Keytruda, Glivec, Afinitor, Jakavi, Zykadia, Halaven and Lenvima. Dr. Yuan is currently Executive Director and Global Lead, Oncology Business Development at Merck. He is in charge of worldwide search and evaluation of clinical stage Oncology assets. In particular, he focuses on expanding Merck’s portfolio in cancer immunotherapy and strengthens Keytruda’s market position in anti-PD1 /PD-L1 class.

Before joining Merck, he held various global commercial positions with increasing responsibilities at Novartis Oncology, most recently as Executive Director and Head, Life Cycle Strategy for Glivec and Afinitor. His other roles included new product planning, early portfolio strategy, and BD evaluation. He participated in global launch of Zykadia in lung cancer and was a core deal team member that successfully in-licensed Jakavi. He was three-time Novartis Oncology President Award recipient. Before joining Novartis, he was global strategic marketing lead for Eisai’s entire Oncology portfolio. Dr. Yuan holds a BS in Biochemistry from Nanjing University, a Ph.D. in Molecular Biology from Columbia University and a MBA from Cornell University.

山东省高校人才招聘会

时间:2016年10月21日周五17:00-19:00pm

地点:The Thomas Laboratory Room 003, The Thomas Building

内容安排:

1. 山东省教育厅领导宣讲国家及山东省海外人才引进政策、人才战略计划;

2. 青岛大学人力资源处负责人介绍青岛大学人才政策及急需重点引进人才的学科领域、专业以及相关生活与工作待遇;

3. 青岛大学药学院院长、首席教授介绍青岛大学的药学、新药研发和生物医学等领域的人才需求专业,现有科研支撑平台和技术能力,未来发展战略和举措;

4. 自由交流。

热烈欢迎教师、博士后、研究生踊跃参加

(招聘会场外提供三明治和饮料等)